
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - In many women, acne can have a hormonal cause that points to a more severe underlying disorder. Being able to appropriately identify such disorders can help dermatologists better treat the acne as well as help prevent more serious long-term selequae.






